title: [The role of matrix metalloproteinases in assessment of prognosis in patients with ST-elevation myocardial infarction during hospital stay].
abstract: Aim of the study was to investigate role of matrix metalloproteinases (MMP) in assessment of prognosis of repetitive cardiovascular events during hospital stay of patients with ST-elevation (STE) myocardial infarction (MI). We consecutively included into this study 175 patients with diagnosis of STEMI. Content of MMP-1, MMP-3 and MMP-9 in blood serum was measured at admission and on day 12 after onset of disease. Levels of all MMPs on day 12 were 1.1-1.6 times higher than on day 1 of MI (<0.05). Comparison of groups of patients with favorable and unfavorable outcome showed that patients with unfavorable outcome had higher median concentrations of MMP-3 and MMP-9 on day 1; this tendency was maintained on day 12. However these differences were significant only for MMP-9. Compared with patients with favorable outcome levels of this marker in patients with unfavorable outcome were higher by 19.4% (=0.04) on day 1 and by 48.8% (=0.03) on day 12. At logistic regression analysis for MMP-9 and unfavorable outcomes during hospital stay area under ROC-curve did not exceed 0.5. But when only inhospital deaths were considered 2 for MMP-9 (day 1) was 14.3 (<0.0001) while area under ROC-curve was 0.72 (0.64; 0.78; =0.02). Thus in patients with STEMI high concentrations of MMP-9 on day 1 of STEMI can come forward as independent marker of unfavorable outcome during hospital stay.
authors: T B
authors: TB
authors: Pecherina
authors: O V
authors: OV
authors: Gruzdeva
authors: V V
authors: VV
authors: Kashtalap
authors: O L
authors: OL
authors: Barbarash
mesh_terms: D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D004562:Electrocardiography; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D012372:ROC Curve; D012008:Recurrence; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D012426:Russia / Q000453:epidemiology; D013997:Time Factors
chemical_list: D015415:Biomarkers; D020780:Matrix Metalloproteinase 9